Pharmacokinetic/Pharmacodynamic Modeling in Drug Development

Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is employed to establish correlation of the concentration-time relationship (PK) with effect-concentration relationship (PD) in order to provide a better understanding of the time course of an effect (PK/PD) after administration of drug1,2,3,4.

[1]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  Michael G. M. Derks,et al.  Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. , 1999, Pulmonary pharmacology & therapeutics.

[3]  N. Holford.  Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.

[4]  H. Derendorf,et al.  Mathematical modeling of cortisol circadian rhythm and cortisol suppression , 1996 .

[5]  R. Mathôt,et al.  Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance , 1999, Clinical pharmacology and therapeutics.

[6]  L. Lesko,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.

[7]  J. Barrett,et al.  Population Pharmacokinetics and Pharmacodynamics of Ciclesonide , 2003, Journal of clinical pharmacology.

[8]  E. R. Garrett,et al.  Psicofuranine: kinetics and mechanisms in vivo with the application of the analog computer. , 1960, The Journal of pharmacology and experimental therapeutics.

[9]  William J. Jusko,et al.  Receptor-mediated pharmacodynamics of prednisolone in the rat , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  D. Drayer,et al.  Hydromorphone levels and pain control in patients with severe chronic pain , 1988, Clinical pharmacology and therapeutics.

[12]  Hartmut Derendorf,et al.  Pharmacokinetic/pharmacodynamic studies in drug product development. , 2002, Journal of pharmaceutical sciences.

[13]  John Anthony Bauer,et al.  Application of Pharmacodynamic Modeling for Designing Time-Variant Dosing Regimens to Overcome Nitroglycerin Tolerance in Experimental Heart Failure , 1997, Pharmaceutical Research.

[14]  B. Lipworth.  The problem of dose-response and therapeutic ratio of inhaled steroids. , 2001, American journal of respiratory and critical care medicine.

[15]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[16]  M. Danhof,et al.  Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[17]  J. C. Matthews.  Fundamentals of Receptor, Enzyme, and Transport Kinetics , 1993 .

[18]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[19]  R. Koopmans,et al.  Pharmacodynamic modelling of the drug-induced downregulation of a β2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone , 2004, European Journal of Clinical Pharmacology.

[20]  M. Karlsson,et al.  Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors , 1999 .

[21]  K. Lasseter,et al.  Population Pharmacokinetics and Pharmacodynamics of Pyridostigmine Bromide for Prophylaxis against Nerve Agents in Humans , 1998, Journal of clinical pharmacology.

[22]  W. Colburn.  Optimizing the Use of Biomarkers, Surrogate Endpoints, and Clinical Endpoints for More Efficient Drug Development , 2000, Journal of clinical pharmacology.

[23]  Younggil Kwon,et al.  Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.

[24]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[25]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[26]  H. Derendorf,et al.  Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. , 1997, International journal of clinical pharmacology and therapeutics.

[27]  E. Zuhowski,et al.  Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Brosstad,et al.  Increased Potency and Decreased Elimination of Lamifiban, a GPIIb-IIIa Antagonist, in Patients with Severe Renal Dysfunction , 1998, Thrombosis and Haemostasis.

[29]  W. Jusko,et al.  Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10 , 1998, Pharmaceutical Research.

[30]  B. Jensen,et al.  Pharmacokinetics and Concentration‐Effect Analysis of Intravenous RGD891, a Platelet GPIIb/IIIa Antagonist, Using Mixed‐Effects Modeling (NONMEM) , 2000, Journal of clinical pharmacology.

[31]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[32]  H Derendorf,et al.  Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. , 1997, International journal of clinical pharmacology and therapeutics.

[33]  S L Shafer,et al.  Pharmacokinetic‐pharmacodynamic modeling in drug development: Application to the investigational opioid trefentanil , 1994, Clinical pharmacology and therapy.

[34]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[35]  S. Khor,et al.  Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. , 2000, The Journal of pharmacology and experimental therapeutics.

[36]  J. Chan,et al.  Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes , 2000, European Journal of Clinical Pharmacology.

[37]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  R. Heinig,et al.  Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form , 1997, European Journal of Clinical Pharmacology.

[39]  S. Mousa,et al.  Disposition and exposure of the fibrinogen receptor antagonist XV459 on αIIBβ3 binding sites in the guinea pig , 1999 .

[40]  M. Gibaldi,et al.  Pharmacokinetics, Second Edition , 1982 .

[41]  S. de Jongh,et al.  The influence of divided doses of drugs on the duration of effect and integral of effect. , 1950, Acta physiologica et pharmacologica Neerlandica.

[42]  B. Jensen,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients , 2000, Journal of clinical pharmacology.

[43]  J. Barrett,et al.  PHARMACOKINETICS AND SAFETY OF A SELEGILINE TRANSDERMAL SYSTEM RELATIVE TO SINGLE‐DOSE ORAL ADMINISTRATION IN THE ELDERLY , 1996, American journal of therapeutics.

[44]  P. Molinoff,et al.  Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. , 1989, Circulation.

[45]  S. Waldman,et al.  Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End‐Stage Renal Insufficiency , 2000, Journal of clinical pharmacology.

[46]  D. Shand,et al.  Plasma concentrations and the time‐course of beta blockade due to propranolol , 1975, Clinical pharmacology and therapeutics.

[47]  T. Müller,et al.  Inhibition of Platelet Aggregation as a Surrogate Marker , 1997, Journal of clinical pharmacology.

[48]  L B Sheiner,et al.  Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.

[49]  Jogarao V. S. Gobburu,et al.  Application of Resampling Techniques to Estimate Exact Significance Levels for Covariate Selection During Nonlinear Mixed Effects Model Building: Some Inferences , 2004, Pharmaceutical Research.

[50]  L B Sheiner,et al.  Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.

[51]  Hartmut Derendorf,et al.  Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.

[52]  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development , 1992 .

[53]  M. Weaver,et al.  Pilocarpine Disposition and Salivary Flow Responses Following Intravenous Administration to Dogs , 1992, Pharmaceutical Research.

[54]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[55]  J L Steimer,et al.  Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[56]  C. Funck-Brentano,et al.  Pharmacokinetic‐pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers , 1998, Clinical pharmacology and therapeutics.

[57]  J. Barrett,et al.  Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century , 2000, Journal of clinical pharmacology.

[58]  H. Derendorf,et al.  Handbook of Pharmacokinetic/Pharmacodynamic Correlation , 1995 .

[59]  R. Straka,et al.  Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[60]  R Bruno,et al.  Pharmacokinetics/Pharmacodynamics in Drug Development: An Industrial Perspective , 2000, Journal of clinical pharmacology.

[61]  P. Rolan,et al.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. , 1995, British journal of clinical pharmacology.

[62]  H. Möllmann,et al.  Pharmacokinetic/Pharmacodynamic Evaluation of Deflazacort in Comparison to Methylprednisolone and Prednisolone , 1995, Pharmaceutical Research.

[63]  M. Bottorff,et al.  Labetalol pharmacokinetics and pharmacodynamics: Evidence of stereoselective disposition , 1990, Clinical pharmacology and therapeutics.

[64]  M. Danhof,et al.  In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.

[65]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[66]  R. Jackson.  A Pharmacokinetic–Pharmacodynamic Model of Chemotherapy of Human Immunodeficiency Virus Infection that Relates Development of Drug Resistance to Treatment Intensity , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[67]  D. Shindler,et al.  A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects , 1997, Journal of clinical pharmacology.

[68]  M Kac,et al.  Some mathematical models in science. , 1969, Science.

[69]  Lewis B. Sheiner,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Pharmaceutical Research.

[70]  N. Holford,et al.  Perioperative Pharmacodynamics of Acetaminophen Analgesia in Children , 1999 .

[71]  B. Jensen,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers , 2000, Journal of clinical pharmacology.

[72]  W. Jusko,et al.  Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. , 1998, The Journal of pharmacology and experimental therapeutics.

[73]  S. Tunn,et al.  Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids , 1993, Journal of clinical pharmacology.